Menactra Antitrust Direct Purchaser Class Action Settlement
All persons or entities in the United States and its territories that purchase Menactra directly from defendant Sanofi Pasteur Inc. (“Sanofi”) or any of its divisions, subsidiaries, predecessors or affiliates, such as VaxServe, Inc., during the period from March 1, 2010 through and including December 31, 2014
You will receive a pro rata share of the settlement after expenses
Proof of Purchase
Adriana M. Castro, et al. v. Sanofi Pasteur Inc., Case No. 2:11-cv-07178-JMV-MAH District Court for the District of New Jersey
This lawsuit claimed that when Novartis was about to enter the MCV4 Vaccine market with its Menveo vaccine, Sanofi, rather than compete on the merits, engaged in illegal conduct to limit competition. Specifically, the lawsuit claimed that, through a series of contracts and other conduct, Sanofi effectively required certain healthcare providers to buy substantially all of their MCV4 Vaccines from Sanofi or risk paying much higher prices on Sanofi’s entire portfolio of pediatric vaccines.